Literature DB >> 23929820

Erythropoietin in patients with acute myocardial infarction: no proof of effectiveness or proof of no effectiveness?

Andrea Messori1, Valeria Fadda, Dario Maratea, Sabrina Trippoli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23929820      PMCID： PMC6649366          DOI： 10.1002/clc.22187

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN： 0160-9289            Impact factor:   2.882


× No keyword cloud information.
  5 in total

1.  Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis.

Authors:  Jørn Wetterslev; Kristian Thorlund; Jesper Brok; Christian Gluud
Journal:  J Clin Epidemiol       Date:  2007-08-23       Impact factor: 6.437

2.  Off-pump versus on-pump coronary artery bypass grafting: quantifying information size by trial sequential analysis.

Authors:  Dario Maratea; Valeria Fadda; Sabrina Trippoli; Andrea Messori
Journal:  Eur J Intern Med       Date:  2013-05-21       Impact factor: 4.487

3.  Same-day discharge after percutaneous coronary intervention: trial sequential analysis of outcomes.

Authors:  Andrea Messori; Valeria Fadda; Dario Maratea; Sabrina Trippoli
Journal:  J Am Coll Cardiol       Date:  2013-10-23       Impact factor: 24.094

4.  Design and rationale of low-dose erythropoietin in patients with ST-segment elevation myocardial infarction (EPO-AMI-II study): a randomized controlled clinical trial.

Authors:  Tetsuo Minamino; Ken Toba; Shuichiro Higo; Daisaku Nakatani; Shungo Hikoso; Masao Umegaki; Kouji Yamamoto; Yoshiki Sawa; Yoshifusa Aizawa; Issei Komuro
Journal:  Cardiovasc Drugs Ther       Date:  2012-10       Impact factor: 3.727

Review 5.  Erythropoietin treatment in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials.

Authors:  Dengfeng Gao; Ning Ning; Xiaolin Niu; Yinhu Dang; Xin Dong; Jin Wei; Canzhan Zhu
Journal:  Am Heart J       Date:  2012-10-16       Impact factor: 4.749
  5 in total
  2 in total

1.  Testing the therapeutic equivalence of alogliptin, linagliptin, saxagliptin, sitagliptin or vildagliptin as monotherapy or in combination with metformin in patients with type 2 diabetes.

Authors:  Andrea Messori; Valeria Fadda; Dario Maratea; Sabrina Trippoli; Claudio Marinai
Journal:  Diabetes Ther       Date:  2014-05-03       Impact factor: 2.945

Review 2.  Signaling Pathways in Cardiac Myocyte Apoptosis.

Authors:  Peng Xia; Yuening Liu; Zhaokang Cheng
Journal:  Biomed Res Int       Date:  2016-12-22       Impact factor: 3.411
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.